Probiotic viability study featured in national press
17 September 2014
A recent study by Dr Simon Gaisford’s group has shed new light on the viability of solid and liquid probiotic formulations and was reported in the Daily Mail, Daily Express, The Times and The Telegraph. It found that liquid products were in general capable of delivering more viable bacteria than solid products. It also suggested that taking products in the fasted state gave the best chance of successful delivery.
A recent study aimed
at exploring some of the myths of oral probiotics has shown that some
commercial probiotic formulations can potentially deliver therapeutic numbers
of probiotic bacteria to the small intestine.
The study was designed to mimic
the challenges faced during oral delivery. These were (i) did the product
provide the stated number of viable bacteria as per the label claim, (ii) could
the bacteria survive exposure to stomach acid and (iii) could the bacteria
thrive upon arrival in the gut?
The study compared 8 commercially available
products. Liquid products (such as yoghurts and aqueous suspensions) generally
fared better than solid products. All liquid products contained equal to or
more than the label claim. Solid products all contained fewer viable bacteria
than the label claim. All products lost viable bacteria when exposed to gastric
fluid. However, four products (Actimel, VSL3, Yakult and Symprove) maintained
viable bacterial numbers for 10 mins and three (Actimel, VSL3 and Symprove)
were viable for up to 90 mins. Following exposure to gastric fluid, the
bacteria in the same three products were shown to grow in growth medium over
The results suggest that these products are capable of delivering viable probiotic species to the gut and indicate that the best way to take them is in the fasted state (to minimise gastric emptying time). Recent data have suggested that probiotics are effective for some conditions (VSL3 for pouchitis and Symprove for IBS) – this study provides a mechanistic explanation for these positive effects. The paper will appear shortly in Beneficial Microbes.
Contact: Dr Simon Gaisford